{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000004","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.592025+00:00","generated_at":"2026-05-16T10:52:30.737870+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Summit submits BLA for ivonescimab in EGFRm NSCLC; $710M cash; GSK collaboration","bullets":["BLA submitted to FDA for ivonescimab + chemo in 2L+ EGFR-mutated NSCLC based on Phase III HARMONi; FDA decision expected Q4 2026.","Preliminary cash, cash equivalents, and short-term investments of ~$710M as of Dec 31, 2025.","Clinical collaboration with GSK to evaluate ivonescimab + risvutatug rezetecan (B7-H3 ADC) across solid tumors; dosing expected mid-2026.","Over 14,000 patients in the US annually eligible for 2L+ treatment of EGFRm NSCLC."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000004","json":"https://secwatch.observer/filing/0001599298-26-000004.json","markdown":"https://secwatch.observer/filing/0001599298-26-000004.md","text":"https://secwatch.observer/filing/0001599298-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000004/0001599298-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000004/smmt-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:52:30.737870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}